<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0230245.ref041">
 <label>41</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Wu</surname>
   <given-names>H</given-names>
  </name>, 
  <name>
   <surname>Pfarr</surname>
   <given-names>DS</given-names>
  </name>, 
  <name>
   <surname>Johnson</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Brewah</surname>
   <given-names>YA</given-names>
  </name>, 
  <name>
   <surname>Woods</surname>
   <given-names>RM</given-names>
  </name>, 
  <name>
   <surname>Patel</surname>
   <given-names>NK</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract</article-title>. 
  <source>J Mol Biol</source>. 
  <year>2007</year>;
  <volume>368</volume>(
  <issue>3</issue>):
  <fpage>652</fpage>â€“
  <lpage>65</lpage>. Epub 2007/02/20. 
  <pub-id pub-id-type="doi">10.1016/j.jmb.2007.02.024</pub-id> .
  <?supplied-pmid 17362988?>
  <pub-id pub-id-type="pmid">17362988</pub-id>
 </mixed-citation>
</ref>
